If you have been reading about synaptogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
The Arabidopsis serpin, AtSerpin1 (At1g47710; 3LE2), mediates set-point control over programmed cell death by targeting the 'Responsive to Desiccation-21' (RD21) papain-like cysteine protease. AtSerpin1 also inhibits metacaspase-like proteases in vitro. Two other Arabidopsis serpins, AtSRP2 (At2g14540) and AtSRP3 (At1g64030) appear to be involved in responses to DNA damage.
==== Including Your Party prior to formation ==== In 2025, Jeremy Corbyn and Zarah Sultana founded a new political party, called Your Party. Prior to the announcement of these plans, polling was carried out about the idea for a hypothetical new party. After the announcement of the plan for a new party, more polling was carried out.
Work on the settlement began in 1843 and it became the capital in July 1845. It was named after Lord Stanley, Secretary of State for War and the Colonies at the time. In 1849, 30 married Chelsea Pensioners were settled there to help with the defence of the islands and to develop the new settlement. The settlement soon grew as a deep-water port, specialising at first in ship repairs; before the construction of the Panama Canal, Port Stanley was a major repair stop for ships travelling through the Straits of Magellan. The rough waters and intense storms found at the tip of the continent forced many ships to Stanley Harbour, and the ship repair industry helped to drive the island economy. Later it became a base for whaling and sealing in the South Atlantic and Antarctic. Later still it was an important coaling station for the Royal Navy. This led to ships based here being involved in the Battle of the Falkland Islands in the First World War, and the Battle of the River Plate in the Second World War. Landslides caused by excessive peat cutting destroyed part of the town in 1879 and again in 1886, which killed two people. At about midnight on 29 November 1878 a black moving mass, several feet high, was moving forwards at a rate of 4 miles per hour (6.4 km/h) or 5 miles per hour (8.0 km/h). The next morning the town was cut in two; the only way to travel between the two parts was by boat. During the Second World War, a hulk in Stanley Harbour was used for interning the British Fascist and Mosleyite Jeffrey Hamm.
He began his campaign by defeating home favourite Matteo Berrettini who retired with an injury. On his way to the title he defeated the top two seeds Djokovic and Medvedev in the semifinals and finals respectively. Due to this win, he became the only player active to have won multiple ATP Finals titles (2) other than Djokovic and Roger Federer, with 7 and 6, respectively.
== Recognition == Mondobiotech received the 2005 Swiss Life Sciences Prize and was included on the World Economic Forum's list of Technology Pioneers for 2008. Cavalli received the 2006 Ernst & Young Entrepreneur of the Year award in Switzerland in the start-up category for Mondobiotech.
Sources: en.wikipedia.org
=== Healthcare === On 11 January, Lula signed into law the "National Policy for the Prevention of Self-Mutilation and Suicide", created by the Health Ministry with the objective of giving mental health support for public security agents. On 20 January, Lula signed a bill, classifying community and disease control agents as health professionals. Also on 20 January, under pressure from religious entities, Lula created the "Department of Support for Therapeutic Communities", aimed at treating drug addicts; after the measure was criticized by human rights organizations, the Ministry of Social Development and Fight against Hunger announced that it would review the decision. The Brazilian Association of Mental Health had also spoken out against the measure in a repudiation note. On 8 March, International Women's Day, Lula announced the creation of the "Programme for the Protection and Promotion of Menstrual Dignity", which provides distribution of menstrual pads by the Sistema Único de Saúde (SUS) to people in vulnerable situations, below the Poverty threshold. The document regulates the Law nº 14.214/2021, which had been vetoed by Jair Bolsonaro in 2021. 8 million people will benefit from the initiative, according to specialists, with an investment of 418 million reals per year, according to the Ministry of Health.
(Full) agonists are able to activate the receptor and result in a strong biological response. The natural endogenous ligand with the greatest efficacy for a given receptor is by definition a full agonist (100% efficacy). Partial agonists do not activate receptors with maximal efficacy, even with maximal binding, causing partial responses compared to those of full agonists (efficacy between 0 and 100%). Antagonists bind to receptors but do not activate them. This results in a receptor blockade, inhibiting the binding of agonists and inverse agonists. Receptor antagonists can be competitive (or reversible), and compete with the agonist for the receptor, or they can be irreversible antagonists that form covalent bonds (or extremely high affinity non-covalent bonds) with the receptor and completely block it. The proton pump inhibitor omeprazole is an example of an irreversible antagonist. The effects of irreversible antagonism can only be reversed by synthesis of new receptors. Inverse agonists reduce the activity of receptors by inhibiting their constitutive activity (negative efficacy). Allosteric modulators: They do not bind to the agonist-binding site of the receptor but instead on specific allosteric binding sites, through which they modify the effect of the agonist. For example, benzodiazepines (BZDs) bind to the BZD site on the GABAA receptor and potentiate the effect of endogenous GABA. Note that the idea of receptor agonism and antagonism only refers to the interaction between receptors and ligands and not to their biological effects.
Although both countries expressed a preference for diplomacy, sharp disagreements persisted and continued to block progress toward an agreement, increasing the risk of a military confrontation. On May 16, Trump sent Iran a nuclear proposal and warned that swift progress was necessary to avoid serious consequences. The Trump administration has increasingly demanded that Iran abandon uranium enrichment, making this a central issue. Khamenei rejected the proposal, dismissing this US demand as "excessive and outrageous". He accused Trump of lying about seeking peace and declared him unworthy of a response. Khamenei also reiterated that Israel is "cancerous tumour" that must be uprooted. On the same day, Trump urged Iran to "move quickly" toward a deal, Iran held talks with European powers in Istanbul about its nuclear negotiations with the US, with Iranian foreign minister Araghchi cautioning that reinstating UN sanctions, which had been lifted under the 2015 nuclear agreement that expired in October, could lead to "irreversible" consequences. On May 20, CNN reported Israel was preparing to strike Iranian nuclear facilities, an action that would mark a clear break with Trump's efforts. Iran warned that any Israeli attack would be met with a "devastating and decisive response." The day after, the US imposed new measures targeting Iran's construction sector, linked to the IRGC, and restricted 10 materials tied to its nuclear and military programs.
An aviation accident is an event during aircraft operation that results in serious injury, death, or significant destruction. An aviation incident is any operating event that compromises safety but does not escalate into an aviation accident. Preventing both accidents and incidents is the primary goal of aviation safety. The most common causes of these accidents and incidents are technical or mechanical failures of the aircraft and pilot error. Adverse weather conditions, including turbulence, thunderstorms, icing, and low visibility, have also historically been major contributing factors in aviation accidents and incidents worldwide. Since civil aviation became widespread in the mid-20th century, hundreds of incidents have occurred every year, with most being minor and non-fatal.
Sources: en.wikipedia.org
==== Limitation on overall itemized deductions ==== Itemized deductions are reduced by 2/37 of the lesser of the amount of the itemized tax deductions or the taxable income that is within the 37%-rate marginal tax bracket. As an exception, the qualified business income deduction under 26 U.S.C. § 199A is not subject to the limitation.
== Description == Parkia biglobosa is a dicotyledonous angiosperm belonging to the family Fabaceae (Caesalpinioideae - Mimosoid clade). It is a deciduous perennial that grows to between 7 and 20 metres high, in some cases up to 30 metres. The tree is a fire-resistant heliophyte characterized by a thick dark gray-brown bark. The pods of the tree, commonly referred to as locust beans, are pink in the beginning and turn dark brown when fully mature. They are 30-40 centimetres long on average, with some reaching lengths of about 45 centimetres. Each pod can contain up to 30 seeds; the seeds are embedded in a sweet, powdery yellow pulp.
=== United States === Pizza Hut's first television commercial was produced in 1965 by Bob Walterscheidt for the Harry Crow agency in Wichita, and was entitled "Putt-Putt to the Pizza Hut". The ad looks just like an old movie and is set in fast motion. It features a man in a business suit and tie, played by Ron Williams, who was then a production manager for Wichita's ABC affiliate KAKE-TV, as he orders take-out, leaves his house, and gets into his 1965 Mustang JR to drive to Pizza Hut, where he is chased by a variety of townspeople, portrayed by neighborhood kids, Walterscheidt and his daughter, and various employees for Harry Crow and KAKE-TV. He goes inside Pizza Hut to pick up his pizza and drives home. People eat all the pizza before the man who ordered it can get any, which makes the man very upset, so he calls Pizza Hut again. The ad first aired on November 19, 1966, during halftime of the Notre Dame vs. Michigan State "Game of the Century", and dramatically increased sales for the franchise. "Putt-Putt to the Pizza Hut" ran on TV for eight years and was nominated for a Clio Award. Until early 2007, Pizza Hut's main advertising slogan was "Gather 'round the good stuff". From 2008 to 2009, the advertising slogan was "Now You're Eating!" From 2009 to 2012, the advertising slogan was "Your Favorites. Your Pizza Hut" From 2012 to 2016, the advertising slogan was "Make it great", a variation of the 1987–1995 slogan "Makin' it great!". From 1995 to 1999, the slogan was "You'll love the stuff we're made of". The advertising slogan is currently "No one outpizzas the hut".
=== Alzheimer's disease === Alzheimer's disease (AD) is a multi-faceted, age-dependent, progressive neurodegenerative disorder, and is a major cause of dementia. According to the Amyloid hypothesis, the accumulation of extracellular amyloid beta peptides (Aβ) into plaques via oligomerization leads to hallmark symptomatic conditions of AD through synaptic dysfunction and neurodegeneration. Immunotherapy via exogenous monoclonal antibody (mAb) administration has been known to treat various central nervous disorders. In the case of AD, immunotherapy is believed to inhibit Aβ-oligomerization or clearing of Aβ from the brain and thereby prevent neurotoxicity. However, mAbs are large molecules and due to the blood–brain barrier, uptake of mAb into the brain is extremely limited, only approximately 1 of 1000 mAb molecules is estimated to pass. However, the Peripheral Sink hypothesis proposes a mechanism where mAbs may not need to cross the blood–brain barrier. Therefore, many research studies are being conducted from failed attempts to treat AD in the past. However, anti-Aβ vaccines can promote antibody-mediated clearance of Aβ plaques in transgenic mice models with amyloid precursor proteins (APP), and can reduce cognitive impairments. Vaccines can stimulate the immune system to produce its own antibodies, in the case of Alzheimer's disease by administration of the antigen Aβ. This is also known as active immunotherapy. Another strategy is so called passive immunotherapy.
== Sources == The compound arenobufagin is one of the major components of certain toad toxins. It is derived from the dried skin of giant toads, such as Bufo gargarizans and Bufo melanostictus Suhneider. Arenobufagin is specifically secreted by Rhinella arenarum, which is found in South America. The toxin of these toad species contains about 1.75% of arenobufagin. The other major part of the venom consists mostly of similar looking bufagins, which are all toxic steroids. Toads produce their toxin when they are scared, injured, or provoked, as a defense mechanism against being eaten by their predators.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.